Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China

doi:10.1007/s11684-014-0331-5

Front. Med.

2014, Vol. 8

Issue (2) : 135-144 https://doi.org/10.1007/s11684-014-0331-5

REVIEW

Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China

Rui Yu, Rong Fan, Jinlin Hou(

)

Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

Download: PDF(262 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

Chronic hepatitis B is a major health problem in China. The universal vaccination program since 1992 has changed the epidemiology of hepatitis B virus infection in China from highly to moderately endemic. The most prevalent hepatitis B virus strains in China are genotypes B and C, whereas those in western provinces are genotypes D and C/D hybrid. Chronic hepatitis B poses a heavy burden to the society in China. Different treatment strategies have been explored to improve patient outcomes in a cost-effective manner. However, antiviral drugs with a low genetic barrier to resistance are still extensively used because of the generally low income and limited resources in China. Individualized antiviral therapy is closely associated with translational medicine, which utilizes information from studies on genomics, immune biomarkers, and fibrosis. The results of these studies are crucial in further improving treatment outcomes.

Keywords chronic hepatitis B epidemiology prevention treatment

Corresponding Author(s): Jinlin Hou

Issue Date: 21 May 2014

Cite this article:

Rui Yu,Rong Fan,Jinlin Hou. Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China[J]. Front. Med., 2014, 8(2): 135-144.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-014-0331-5
https://academic.hep.com.cn/fmd/EN/Y2014/V8/I2/135

Fig.1 Distribution of antiviral drugs for chronic hepatitis B used in clinical practice in China. June 2012 to December 2013 (Data from 31905 patients enrolled in treatment survey in China Registry of Hepatitis B). CHB, chronic hepatitis B; NAs, nucleos(t)ide analogs. IFNs, interferons; LAM, lamivudine; ETV, entecavir; ADV, adefovir; TDF, tenofovir; LDT, telbivudine. ^a including hepatic protectant, immunomodulator, traditional Chinese medicine and drugs unknown.

Tab.1 Latest results of major clinical studies on the efficacy and drug- resistance of nucleos(t)ide analogs

Fig.2 Response-guided therapy for pegylated interferon treatment in patients with chronic hepatitis B.

1	World Health Organization. Hepatitis B. (Revised July 2013). [2010-30]
2	D Ganem, AM Prince. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med 2004; 350(11): 1118–1129 https://doi.org/10.1056/NEJMra031087 pmid: 15014185
3	HL Chan, JJ Sung. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006; 26(2): 153–161 https://doi.org/10.1055/s-2006-939753 pmid: 16673293
4	X Liang, S Bi, W Yang, L Wang, G Cui, F Cui, Y Zhang, J Liu, X Gong, Y Chen, F Wang, H Zheng, F Wang, J Guo, Z Jia, J Ma, H Wang, H Luo, L Li, S Jin, SC Hadler, Y Wang. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009; 27(47): 6550–6557 https://doi.org/10.1016/j.vaccine.2009.08.048 pmid: 19729084
5	S Schaefer. Hepatitis B virus: significance of genotypes. J Viral Hepat 2005; 12(2): 111–124 https://doi.org/10.1111/j.1365-2893.2005.00584.x pmid: 15720525
6	G Zeng, Z Wang, S Wen, J Jiang, L Wang, J Cheng, D Tan, F Xiao, S Ma, W Li, K Luo, NV Naoumov, J Hou. Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China. J Viral Hepat 2005; 12(6): 609–617 https://doi.org/10.1111/j.1365-2893.2005.00657.x pmid: 16255762
7	Z Wang, Z Liu, G Zeng, S Wen, Y Qi, S Ma, NV Naoumov, J Hou. A new intertype recombinant between genotypes C and D of hepatitis B virus identified in China. J Gen Virol 2005; 86(Pt 4): 985–990 https://doi.org/10.1099/vir.0.80771-0 pmid: 15784891
8	B Zhou, L Xiao, Z Wang, ET Chang, J Chen, J Hou. Geographical and ethnic distribution of the HBV C/D recombinant on the Qinghai-Tibet Plateau. PLoS One 2011; 6(4): e18708 https://doi.org/10.1371/journal.pone.0018708 pmid: 21494570
9	B Zhou, Z Wang, J Yang, J Sun, H Li, Y Tanaka, M Mizokami, J Hou. Novel evidence of HBV recombination in family cluster infections in western China. PLoS One 2012; 7(6): e38241 https://doi.org/10.1371/journal.pone.0038241 pmid: 22675528
10	CJ Chen, HI Yang, J Su, CL Jen, SL You, SN Lu, GT Huang, UH Iloeje; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295(1): 65–73 https://doi.org/10.1001/jama.295.1.65 pmid: 16391218
11	European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57(1): 167–185 pmid: 22436845
12	YF Liaw, JH Kao, T Piratvisuth, H Chan, RN Chien, CJ Liu, E Gane, S Locarnini, SG Lim, KH Han, D Amarapurkar, G Cooksley, W Jafri, R Mohamed, JL Hou, WL Chuang, L Lesmana, J Sollano, DJ Suh, M Omata. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatology International 2012; 6(3): 531–561 https://doi.org/10.1007/s12072-012-9365-4
13	AS Lok, BJ McMahon. Chronic hepatitis B: update 2009. Hepatology 2009; 50(3): 661–662 https://doi.org/10.1002/hep.23190 pmid: 19714720
14	MJ Sonneveld, BE Hansen, T Piratvisuth, JD Jia, S Zeuzem, E Gane, YF Liaw, Q Xie, EJ Heathcote, HL Chan, HL Janssen. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013; 58(3): 872–880 https://doi.org/10.1002/hep.26436 pmid: 23553752
15	J Hou, H Ma, J Sun, Q Xie, Y Xie, Y Sun, H Wang, G Shi, M Wan, J Niu, Q Ning, Y Yu, Y Zhao. Response guided peginterferon alfa-2a (PegIFN alfa-2a) therapy in patients with HBeAg-positive chronic hepatitis B (CHB). J Hepatol 2014[Epub ahead of print] (abstract)
16	V Rijckborst, BE Hansen, Y Cakaloglu, P Ferenci, F Tabak, M Akdogan, K Simon, US Akarca, R Flisiak, E Verhey, AJ Van Vuuren, CA Boucher, MJ ter Borg, HL Janssen. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52(2): 454–461 https://doi.org/10.1002/hep.23722 pmid: 20683945
17	Q Ning, M Han, Y Sun, JJ Jiang, D Tan, J Hou, H Tang, JF Sheng, M Jiang. Patients with HBeAg-positive chronic hepatitis B (CHB) with a maintained virological response to entecavir achieved HBsAg clearance when switched to peginterferon alfa-2a therapy (the OSST study). Hepatology 2011; 54(Suppl): 1010–1A
18	HL Chan. Peginterferon therapy for chronic hepatitis B: one size fits all? Gut 2013; 62(2): 185–187 https://doi.org/10.1136/gutjnl-2012-303291 pmid: 22942237
19	DJ Tenney, KA Pokornowski, RE Rose, CJ Baldick, BJ Eggers, J Fang, MJ Wichroski, UA Diva, D Xu, RB Wilber, H Brett-Smith, UH Iloeje. 20 entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients. J Hepatol 2009; 50(Suppl): S10 https://doi.org/10.1016/S0168-8278(09)60022-2
20	O Yokosuka, K Takaguchi, S Fujioka, M Shindo, K Chayama, H Kobashi, N Hayashi, C Sato, K Kiyosawa, K Tanikawa, H Ishikawa, N Masaki, T Seriu, M Omata. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol 2010; 52(6): 791–799 https://doi.org/10.1016/j.jhep.2009.12.036 pmid: 20409606
21	EJGP Marcellin, N Tsai, R Flisiak, SGJ Petersen, IA Kotzev, JF Flaherty, P Dinh, A Gaggar, KM Kitrinos, M Subramanian, JG McHutchison, J George, M Buti. Seven years of treatment with tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance. Hepatology 2013; 58(S1): 649A
22	P Marcellin, E Gane, M Buti, N Afdhal, W Sievert, IM Jacobson, MK Washington, G Germanidis, JF Flaherty, RA Schall, JD Bornstein, KM Kitrinos, GM Subramanian, JG McHutchison, EJ Heathcote. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381(9865): 468–475 https://doi.org/10.1016/S0140-6736(12)61425-1 pmid: 23234725
23	AS Lok, CL Lai, N Leung, GB Yao, ZY Cui, ER Schiff, JL Dienstag, EJ Heathcote, NR Little, DA Griffiths, SD Gardner, M Castiglia. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125(6): 1714–1722 https://doi.org/10.1053/j.gastro.2003.09.033 pmid: 14724824
24	SJ Hadziyannis, NC Tassopoulos, EJ Heathcote, TT Chang, G Kitis, M Rizzetto, P Marcellin, SG Lim, Z Goodman, J Ma, CL Brosgart, K Borroto-Esoda, S Arterburn, Chuck SL; Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131(6): 1743–1751 https://doi.org/10.1053/j.gastro.2006.09.020 pmid: 17087951
25	MF Yuen, E Sablon, CK Hui, HJ Yuan, H Decraemer, CL Lai. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34(4): 785–791
26	HB Chae, HW Hann, CK Hui, HJ Yuan, H Decraemer, CL Lai. Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol 2007; 13(30): 4085–4090 pmid: 17696226
27	YF Liaw, E Gane, N Leung, S Zeuzem, Y Wang, CL Lai, EJ Heathcote, M Manns, N Bzowej, J Niu, SH Han, SG Hwang, Y Cakaloglu, MJ Tong, G Papatheodoridis, Y Chen, NA Brown, E Albanis, K Galil, NV Naoumov; GLOBE Study Group. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136(2): 486–495 https://doi.org/10.1053/j.gastro.2008.10.026 pmid: 19027013
28	HW Hann. Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses. Expert Opin Pharmacother 2010; 11(13): 2243–2249 https://doi.org/10.1517/14656566.2010.512437 pmid: 20698726
29	JJ Sung, JY Lai, S Zeuzem, WC Chow, EJ Heathcote, RP Perrillo, CL Brosgart, MA Woessner, SA Scott, DF Gray, SD Gardner. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008; 48(5): 728–735 https://doi.org/10.1016/j.jhep.2007.12.026 pmid: 18329126
30	CK Hui, HY Zhang, S Bowden, S Locarnini, JM Luk, KW Leung, YH Yueng, A Wong, F Rousseau, KY Yuen, NN Naoumov, GK Lau. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 2008; 48(5): 714–720 https://doi.org/10.1016/j.jhep.2007.10.013 pmid: 18207280
31	AS1 Lok, H Trinh, G Carosi, US Akarca, A Gadano, F Habersetzer, W Sievert, D Wong, M Lovegren, D Cohen, C Llamoso. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology 2012; 143(3): 619–28 e1 pmid: 22643350
32	NA Terrault. Benefits and risks of combination therapy for hepatitis B. Hepatology 2009; 49(5 Suppl): S122–S128 https://doi.org/10.1002/hep.22921 pmid: 19399796
33	EB Keeffe, S Zeuzem, RS Koff, DT Dieterich, R Esteban-Mur, EJ Gane, IM Jacobson, SG Lim, N Naoumov, P Marcellin, T Piratvisuth, F Zoulim. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5(8): 890–897 https://doi.org/10.1016/j.cgh.2007.05.004 pmid: 17632041
34	J Sun, Q Xie, D Tan, Q Ning, J Niu, X Bai, R Fan, S Chen, J Cheng, Y Yu, H Wang, M Xu, G Shi, M Wan, X Chen, H Tang, J Sheng, X Dou, J Shi, H Ren, M Wang, H Zhang, Z Gao, C Chen, H Ma, J Jia, J Hou. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology 2014; 59(4): 1283–1292 pmid: 24382690
35	MG Peters, Hw Hann Hw, P Martin, EJ Heathcote, P Buggisch, R Rubin, M Bourliere, K Kowdley, C Trepo, Df Gray Df, M Sullivan, K Kleber, R Ebrahimi, S Xiong, CL Brosgart. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126(1): 91–101 https://doi.org/10.1053/j.gastro.2003.10.051 pmid: 14699491
36	I Rapti, E Dimou, P Mitsoula, SJ Hadziyannis. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45(2): 307–313 https://doi.org/10.1002/hep.21534 pmid: 17256746
37	P Lampertico, M Viganò, E Manenti, M Iavarone, E Sablon, M Colombo. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133(5): 1445–1451 https://doi.org/10.1053/j.gastro.2007.08.079 pmid: 17983801
38	H Yang, X Qi, A Sabogal, M Miller, S Xiong, WE Delaney 4th. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10(5): 625–633 pmid: 16152756
39	O Lada, Y Benhamou, A Cahour, C Katlama, T Poynard, V Thibault. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004; 9(3): 353–363 pmid: 15259898
40	J Sun, JL Hou, Q Xie, XH Li, JM Zhang, YM Wang, H Wang, JY Lai, SJ Chen, JD Jia, JF Sheng, HL Chan, JF Wang, MK Li, M Jiang, M Popescu, JJ Sung. Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. Aliment Pharmacol Ther 2011; 34(4): 424–431 https://doi.org/10.1111/j.1365-2036.2011.04750.x pmid: 21692822
41	T Berg, P Marcellin, F Zoulim, B Moller, H Trinh, S Chan, E Suarez, F Lavocat, A Snow-Lampart, D Frederick, J Sorbel, K Borroto-Esoda, D Oldach, F Rousseau. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 2010; 139(4): 1207–1217, e3 https://doi.org/10.1053/j.gastro.2010.06.053 pmid: 20600025
42	M Sherman, C Yurdaydin, J Sollano, M Silva, YF Liaw, J Cianciara, A Boron-Kaczmarska, P Martin, Z Goodman, R Colonno, A Cross, G Denisky, B Kreter, R Hindes; AI463026 BEHoLD Study Group. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130(7): 2039–2049 https://doi.org/10.1053/j.gastro.2006.04.007 pmid: 16762627
43	M Sherman, C Yurdaydin, H Simsek, M Silva, YF Liaw, VK Rustgi, H Sette, N Tsai, DJ Tenney, J Vaughan, B Kreter, R Hindes; AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48(1): 99–108 https://doi.org/10.1002/hep.22323 pmid: 18537189
44	J Petersen, V Ratziu, M Buti, HL Janssen, A Brown, P Lampertico, J Schollmeyer, F Zoulim, H Wedemeyer, M Sterneck, T Berg, C Sarrazin, M Lutgehetmann, P Buggisch. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol 2012; 56(3): 520–526 https://doi.org/10.1016/j.jhep.2011.09.018 pmid: 22037226
45	W Chotiyaputta, C Peterson, FA Ditah, D Goodwin, AS Lok. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol 2011; 54(1): 12–18 https://doi.org/10.1016/j.jhep.2010.06.016 pmid: 20888661
46	E Domingo. Viruses at the edge of adaptation. Virology 2000; 270(2): 251–253 https://doi.org/10.1006/viro.2000.0320 pmid: 10792982
47	C Rodriguez, S Chevaliez, P Bensadoun, JM Pawlotsky. Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing. Hepatology 2013; 58(3): 890–901 https://doi.org/10.1002/hep.26383 pmid: 23505208
48	SW Ma, X Huang, YY Li, LB Tang, XF Sun, XT Jiang, YX Zhang, J Sun, ZH Liu, WG Abbott, YH Dong, NV Naoumov, JL Hou. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. J Hepatol 2012; 56(4): 775–781 https://doi.org/10.1016/j.jhep.2011.10.020 pmid: 22173154
49	Y Li, S Ma, L Tang, Y Li, W Wang, X Huang, Q Lai, M Zhang, J Sun, CK Li, WG Abbott, NV Naoumov, Y Zhang, J Hou. Circulating chemokine (C-X-C Motif) receptor 5(+) CD4(+) T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection. Hepatology 2013; 58(4): 1277–1286 https://doi.org/10.1002/hep.26489 pmid: 23703545
50	VW Wong, HL Chan. Transient elastography. J Gastroenterol Hepatol 2010; 25(11): 1726–1731 https://doi.org/10.1111/j.1440-1746.2010.06437.x pmid: 21039833
51	HL Chan, GL Wong, PC Choi, AW Chan, AM Chim, KK Yiu, FK Chan, JJ Sung, VW Wong. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009; 16(1): 36–44 https://doi.org/10.1111/j.1365-2893.2008.01037.x pmid: 18673426
52	YP Chen, XE Liang, L Dai, Q Zhang, J Peng, YF Zhu, WQ Wen, HL Chan, JL Hou. Improving transient elastography performance for detecting hepatitis B cirrhosis. Dig Liver Dis 2012; 44(1): 61–66 https://doi.org/10.1016/j.dld.2011.08.004 pmid: 21907650
53	YP Chen, Q Zhang, L Dai, XE Liang, J Peng, JL Hou. Is transient elastography valuable for high-risk esophageal varices prediction in patients with hepatitis-B-related cirrhosis? J Gastroenterol Hepatol 2012; 27(3): 533–539 https://doi.org/10.1111/j.1440-1746.2011.06889.x pmid: 21871027

[1]	Yi Zhang, Haocheng Zhang, Wenhong Zhang. SARS-CoV-2 variants, immune escape, and countermeasures[J]. Front. Med., 2022, 16(2): 196-207.
[2]	Jing Wang, Zequn Lu, Meng Jin, Ying Wang, Kunming Tian, Jun Xiao, Yimin Cai, Yanan Wang, Xu Zhang, Tao Chen, Zhi Yao, Chunguang Yang, Renli Deng, Qiang Zhong, Xiongbo Deng, Xin Chen, Xiang-ping Yang, Gonghong Wei, Zhihua Wang, Jianbo Tian, Xiao-ping Chen. Clinical characteristics and risk factors of COVID-19 patients with chronic hepatitis B: a multi-center retrospective cohort study[J]. Front. Med., 2022, 16(1): 111-125.
[3]	Chun Cai, Yuexing Liu, Yanyun Li, Yan Shi, Haidong Zou, Yuqian Bao, Yun Shen, Xin Cui, Chen Fu, Weiping Jia, the SIM Study Group. Effectiveness of quality of care for patients with type 2 diabetes in China: findings from the Shanghai Integration Model (SIM)[J]. Front. Med., 2022, 16(1): 126-138.
[4]	William J. Liu, Haixia Xiao, Lianpan Dai, Di Liu, Jianjun Chen, Xiaopeng Qi, Yuhai Bi, Yi Shi, George F. Gao, Yingxia Liu. Avian influenza A (H7N9) virus: from low pathogenic to highly pathogenic[J]. Front. Med., 2021, 15(4): 507-527.
[5]	Wei Zhang, Bixiang Zhang, Xiao-ping Chen. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma[J]. Front. Med., 2021, 15(2): 155-169.
[6]	Solmaz Ohadian Moghadam, Seyed Ali Momeni. Human microbiome and prostate cancer development: current insights into the prevention and treatment[J]. Front. Med., 2021, 15(1): 11-32.
[7]	Ke Sheng. Artificial intelligence in radiotherapy: a technological review[J]. Front. Med., 2020, 14(4): 431-449.
[8]	Cenyi Shao, Shijian Li, Feng Zhu, Dahai Zhao, Hui Shao, Haixiao Chen, Zhiruo Zhang. Taizhou’s COVID-19 prevention and control experience with telemedicine features[J]. Front. Med., 2020, 14(4): 506-510.
[9]	Honglu Zhou, Songmei Wang, Lorenz von Seidlein, Xuanyi Wang. The epidemiology of norovirus gastroenteritis in China: disease burden and distribution of genotypes[J]. Front. Med., 2020, 14(1): 1-7.
[10]	Xiaoxin Wu, Lanlan Xiao, Lanjuan Li. Research progress on human infection with avian influenza H7N9[J]. Front. Med., 2020, 14(1): 8-20.
[11]	Tung Huynh, Ke-Qin Hu. Direct acting antiviral-induced dynamic reduction of serum α fetoprotein in hepatitis C patients without hepatocellular carcinoma[J]. Front. Med., 2019, 13(6): 658-666.
[12]	Jing Yue, Bo Zhang, Mingyue Wang, Junning Yao, Yifan Zhou, Ding Ma, Lei Jin. Effect of antitubercular treatment on the pregnancy outcomes and prognoses of patients with genital tuberculosis[J]. Front. Med., 2019, 13(1): 121-125.
[13]	Eun Young Lee, Kun-Ho Yoon. Epidemic obesity in children and adolescents: risk factors and prevention[J]. Front. Med., 2018, 12(6): 658-666.
[14]	Minhong Shen, Yibin Kang. Complex interplay between tumor microenvironment and cancer therapy[J]. Front. Med., 2018, 12(4): 426-439.
[15]	Kuo Yang, Runshun Zhang, Liyun He, Yubing Li, Wenwen Liu, Changhe Yu, Yanhong Zhang, Xinlong Li, Yan Liu, Weiming Xu, Xuezhong Zhou, Baoyan Liu. Multistage analysis method for detection of effective herb prescription from clinical data[J]. Front. Med., 2018, 12(2): 206-217.

Viewed

Full text

Abstract

Cited

Shared

Discussed